TCRX

Tscan Therapeutics Inc

TCRX.US tscan.com + Research + Basket
CIK 0001783328
Employees 138
Phone 857 399 9500
Fiscal year end December
IPO Jul 16, 2021
Address 830 Winter Street, Waltham, MA, United States, 02451
0.19
0.00 (-0.44%)
USD · NASDAQ
52-week range
0.18
2.01
Trading at 1% of the 52-week range
Market Cap
13.01M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.02
Div. Yield
N/A
% Institutions
67.88%
% Insiders
0.189%

1 Year

-91.6%

3 Year

-95.2%

10 Year

-98.2%
Description

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Actions

Add an action for TCRX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Gavin MacBeath Ph.D. CEO, Principal Financial Officer, Principal Accounting Officer & Director 1970
Dr. Stephen J. Elledge Ph.D. Co-Founder & Chairman of Scientific Advisory Board NA
Mr. Tomasz Kula Ph.D. Co-Founder & Member of Advisory Board NA
Dr. Zoran Zdraveski J.D., Ph.D. Chief Legal & Strategy Officer and Company Secretary 1970
Ms. Ann Hargraves Chief Human Resources Officer NA
Dr. Shrikanta Chattopadhyay M.D. Senior VP & Head of Translational Medicine NA
Mr. Jim Murray Chief Development Operations Officer NA
Mr. Cagan Gurer Ph.D. Senior Vice President of Discovery NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Dec 23, 2025 Lynx1 Capital Management Lp N/A Purchase 6.23K $0.90 $5.61K SEC
Dec 22, 2025 Lynx1 Capital Management Lp N/A Purchase 75.50K $0.90 $67.95K SEC
Dec 19, 2025 Lynx1 Capital Management Lp N/A Purchase 80.07K $0.90 $72.06K SEC
May 20, 2025 Lynx1 Capital Management Lp N/A Purchase 1.20M $1.20 $1.44M SEC
May 19, 2025 Lynx1 Capital Management Lp N/A Purchase 1.39M $1.20 $1.67M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Lynx1 Capital Management, LP 8.02M Jun 30, 2026 11.83% $0.91 0.00%
Bvf Inc 5.56M Jun 30, 2026 8.21% $0.14 0.00%
Baker Bros Advisors LP 2.78M Jun 30, 2026 4.11% $0.01 0.00%
Vanguard Capital Management, LLC 2.16M Jun 30, 2026 3.19% $0.00 0.21%
Two Sigma Investments LLC 1.95M Jun 30, 2026 2.88% $0.00 61.26%
Renaissance Technologies Corp 1.33M Jun 30, 2026 1.96% $0.00 -2.78%
Acadian Asset Management LLC 1.31M Jun 30, 2026 1.93% $0.00 546.50%
Deer Management Co. LLC 1.25M Jun 30, 2026 1.84% $0.15 0.00%
Millennium Management LLC 1.16M Jun 30, 2026 1.72% $0.00 -20.32%
Jacobs Levy Equity Management, Inc. 1.05M Jun 30, 2026 1.55% $0.00 29.87%
Citadel Advisors Llc 1.01M Jun 30, 2026 1.49% $0.00 216.92%
BlackRock Inc 994.65K Jun 30, 2026 1.47% $0.00 -45.97%
Kalehua Capital Management LLC 909.75K Jun 30, 2026 1.34% $0.28 0.00%
BOOTHBAY FUND MANAGEMENT, LLC 772.24K Jun 30, 2026 1.14% $0.01 0.00%
Marshall Wace Asset Management Ltd 687.36K Jun 30, 2026 1.01% $0.00 189.60%
DC Funds, LP 630.00K Jun 30, 2026 0.93% $49.27 0.00%
Geode Capital Management, LLC 584.81K Jun 30, 2026 0.86% $0.00 -5.21%
D. E. Shaw & Co LP 548.40K Jun 30, 2026 0.81% $0.00 71.60%
GSA Capital Partners LLP 548.09K Jun 30, 2026 0.81% $0.03 44.63%
Vanguard Fiduciary Trust Co 363.95K Jun 30, 2026 0.54% $0.00 19.03%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.84M 2.72% ▲ 0.00% Sep 30, 2026
2 Fidelity Extended Market Index 328.92K 0.49% ▲ 9.77% Aug 31, 2026
3 BlackRock Health Sciences Term Trust 265.57K 0.39% ▼ 34.75% Jun 30, 2026
4 iShares Micro-Cap ETF 159.82K 0.24% ▼ 0.68% Sep 30, 2026
5 BSF Systematic US Eq Abs Ret A2 USD 142.63K 0.21% ▲ 0.00% Dec 31, 2025
6 Fidelity Total Market Index 87.57K 0.13% ▲ 0.00% Aug 31, 2026
7 Fidelity Series Total Market Index 72.91K 0.11% ▲ 0.00% Aug 31, 2026
8 EA Bridgeway Ultra-Small Company Mkt ETF 69.44K 0.10% ▲ 0.00% Sep 30, 2026
9 NVIT Small Cap Val I 39.00K 0.06% ▲ 0.00% Jun 30, 2026
10 Vanguard U.S. Eq Idx £ Acc 15.71K 0.02% ▲ 0.00% Sep 30, 2026

Financial Highlights

▼
Market Cap: $13.01M
EBITDA: $-115.66M
Book Value: $1.02
Earnings/Share: $-0.91
Profit Margin: 0.00%
Operating Margin: -2,901.33%
ROA (TTM): -31.53%
ROE (TTM): -95.81%
Revenue (TTM): $7.11M
Revenue/Share (TTM): $0.11
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -65.80%

Valuation Metrics

Enterprise Value: $3.59M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 63.50M
Shares Float: 54.36M
% Insiders: 0.189%
% Institutions: 67.88%
Short % Float: 4.83%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$10.33M
Cost of Goods Sold
adjust
$-2.87M
Gross Profit
subtotal
$7.46M
SG&A
adjust
$-31.99M
R&D
adjust
$-114.15M
Operating Income
subtotal
$-135.81M
Other / Non-Operating Items
adjust
$6.05M
Net Income
subtotal
$-129.77M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TCRX.US!